AB
KLRS

Amalgamated Bank’s Kalaris Therapeutics KLRS Stock Holding History

Amalgamated Bank’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-45
Closed -$1K – 3128
2024
Q1 		$1K Sell
45
-79
-64% -$1.29K ﹤0.01% 2943
2023
Q4 		$2K Sell
124
-13
-9% -$513 ﹤0.01% 2983
2023
Q3 		$7K Hold
137
– – ﹤0.01% 2954
2023
Q2 		$11K Hold
137
– – ﹤0.01% 2946
2023
Q1 		$12K Sell
137
-31
-18% -$3.95K ﹤0.01% 2784
2022
Q4 		$20K Hold
168
– – ﹤0.01% 2756
2022
Q3 		$31K Hold
168
– – ﹤0.01% 2662
2022
Q2 		$15K Sell
168
-41
-20% -$4.3K ﹤0.01% 2922
2022
Q1 		$33K Buy
+209
New +$41.7K ﹤0.01% 2645

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Bank's KLRS Position: Q2 2024 in Review

Amalgamated Bank sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 45 shares — an estimated $1K sold.

Amalgamated Bank first reported a position in KLRS in Q1 2022 and held it in 9 quarters. The position peaked at $33K in Q1 2022. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • Amalgamated Bank reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Amalgamated Bank sold 45 Kalaris Therapeutics shares in Q2 2024, an estimated $1K.
  • Amalgamated Bank first reported a position in Kalaris Therapeutics in Q1 2022 and held it in 9 quarters.
  • Amalgamated Bank's Kalaris Therapeutics position peaked at $33K in Q1 2022.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Amalgamated Bank's 13F filing for Q2 2024, filed 12 Aug 2024.